Success Metrics

Clinical Success Rate
83.3%

Based on 15 completed trials

Completion Rate
83%(15/18)
Active Trials
2(9%)
Results Posted
100%(15 trials)
Terminated
3(13%)

Phase Distribution

Ph phase_2
9
39%
Ph early_phase_1
1
4%
Ph phase_3
7
30%
Ph phase_1
4
17%
Ph phase_4
1
4%

Phase Distribution

5

Early Stage

9

Mid Stage

8

Late Stage

Phase Distribution22 total trials
Early Phase 1First-in-human
1(4.5%)
Phase 1Safety & dosage
4(18.2%)
Phase 2Efficacy & side effects
9(40.9%)
Phase 3Large-scale testing
7(31.8%)
Phase 4Post-market surveillance
1(4.5%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

83.3%

15 of 18 finished

Non-Completion Rate

16.7%

3 ended early

Currently Active

2

trials recruiting

Total Trials

23

all time

Status Distribution
Active(4)
Completed(15)
Terminated(3)
Other(1)

Detailed Status

Completed15
Terminated3
Recruiting2
Not yet recruiting1
unknown1
Enrolling by invitation1

Development Timeline

Analytics

Development Status

Total Trials
23
Active
2
Success Rate
83.3%
Most Advanced
Phase 4

Trials by Phase

Early Phase 11 (4.5%)
Phase 14 (18.2%)
Phase 29 (40.9%)
Phase 37 (31.8%)
Phase 41 (4.5%)

Trials by Status

completed1565%
not_yet_recruiting14%
recruiting29%
terminated313%
unknown14%
enrolling_by_invitation14%

Recent Activity

Clinical Trials (23)

Showing 20 of 23 trialsScroll for more
NCT07553767Early Phase 1

Efficacy and Safety of Pegylated Interferon Alpha-2β in Patients With Hepatitis B-related Hepatocellular Carcinoma After Radical Resection

Not Yet Recruiting
NCT07542951Phase 4

TAF vs TDF During the Pregancy

Enrolling By Invitation
NCT05861674Phase 2

A Study to Assess Efficacy and Safety of HH-003 Injection in Subjects With Chronic Hepatitis Delta Virus Infection

Completed
NCT02932150Phase 2

Study of Tenofovir Alafenamide (TAF) in Children and Teen Participants With Chronic Hepatitis B Virus Infection

Recruiting
NCT07307586Phase 3

A Small Sample Prospective Clinical Study of Azvudine Tablets to Promote Clinical Cure in Patients With Chronic Hepatitis B

Recruiting
NCT05123599Phase 1

A Study of JNJ-73763989, JNJ-64300535, and Nucleos(t)Ide Analogs in Virologically Suppressed, Hepatitis B e Antigen (HBeAg)- Negative Participants With Chronic Hepatitis B Virus Infection

Completed
NCT02836249Phase 3

Tenofovir Alafenamide Versus Tenofovir Disoproxil Fumarate for Treatment of Hepatitis B e Antigen-Positive Hepatitis B (China)

Completed
NCT04143594Phase 2

Study to Evaluate the Safety and Efficacy of Lenacapavir (GS-6207) in Combination With Other Antiretroviral Agents in People Living With HIV

Completed
NCT02836236Phase 3

Tenofovir Alafenamide Versus Tenofovir Disoproxil Fumarate for Treatment of Hepatitis B e Antigen-Negative Hepatitis B (China)

Completed
NCT05005507Phase 2

A Study of JNJ-73763989, Pegylated Interferon Alpha-2a and Nucleos(t)Ide Analogs in Participants With Chronic Hepatitis B Virus Infection

Terminated
NCT01940471Phase 3

Study to Compare Tenofovir Alafenamide (TAF) Versus Tenofovir Disoproxil Fumarate (TDF) in Participants With Chronic Hepatitis B Infection Who Are Positive for Hepatitis B e Antigen

Completed
NCT01940341Phase 3

Study to Compare Tenofovir Alafenamide (TAF) Versus Tenofovir Disoproxil Fumarate (TDF) in Participants With Chronic Hepatitis B Infection Who Are Negative for Hepatitis B e Antigen

Completed
NCT02862548Phase 2

Efficacy and Safety of Tenofovir Alafenamide (TAF) Versus Tenofovir Disoproxil Fumarate (TDF)-Containing Regimens in Participants With Chronic Hepatitis B Virus (HBV) Infection and Stage 2 or Greater Chronic Kidney Disease Who Have Received a Liver Transplant

Completed
NCT04551261Phase 1

GLS4/RTV and TAF Drug-drug Interaction

Completed
NCT03615066Phase 2

Study to Evaluate the Safety, Tolerability, and Antiviral Activity of Selgantolimod (Formerly GS-9688) in Viremic Adult Participants With Chronic Hepatitis B (CHB) Who Are Not Currently on Treatment

Completed
NCT03434353Phase 2

Study to Evaluate the Safety and Antiviral Activity of Inarigivir Soproxil (Formerly: GS-9992) Plus Tenofovir Alafenamide (TAF) for 12 Weeks in Adults With Chronic Hepatitis B (CHB)

Terminated
NCT03180619Phase 2

Study to Evaluate the Safety and Efficacy of Switching to Tenofovir Alafenamide (TAF) From Tenofovir Disoproxil Fumarate (TDF) and/or Other Oral Antiviral Treatment (OAV)

Completed
NCT03739866Phase 1

Study to Evaluate Safety, Pharmacokinetics, and Antiviral Activity of Lenacapavir Administered Subcutaneously in Human Immunodeficiency Virus (HIV) -1 Infected Adults

Completed
NCT03472326Phase 2

Study to Evaluate the Efficacy of GS-9131 Functional Monotherapy in Human Immunodeficiency Virus (HIV)-1-Infected Adults Failing a Nucleos(t)Ide Reverse Transcriptase Inhibitor-Containing Regimen With Nucleos(t)Ide Reverse Transcriptase Inhibitor Resistant Virus

Terminated
NCT02296853Phase 1

Study to Evaluate the Pharmacokinetics of Tenofovir Alafenamide (TAF) in Adults With Normal Hepatic Function and Adults With Severe Hepatic Impairment

Completed

Drug Details

Intervention Type
DRUG
Total Trials
23